Summary: Researchers collaborated to conduct a comprehensive study on multiple myeloma at the molecular level, identifying early detection methods for aggressive tumors based on changes in genetic material affecting protein profiles. Takeaways:. Heterogeneous Disease Progression: Multiple myeloma exhibits diverse progression rates and aggressiveness among patients, complicating treatment predictions and outcomes.

Multiple Myeloma: Mass Spectrometry Aids Early Detection

Results of the Phase III CARTITUDE-4 study showed that treatment with Carvykti achieved a more significant improvement in overall survival (OS) compared to standard therapies. Results from the second interim analysis of the Phase III CARTITUDE-4 study, which evaluated Johnson & Johnson’s (J&J) Carvykti (ciltacabtagene autoleucel; cilta-cel) for patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy showed that the treatment achieved a statistically significant and clinically meaningful improvement in overall survival (OS) compared to standard therapies such as omalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1.

Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma. In part 1 of an interview, Suzanne Lentzsch, MD, PhD, director of the multiple myeloma and...

Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy. Equecabtagene autoleucel (eque-cel; IASO Bio) has demonstrated efficacy and safety in treating patients with high-risk newly diagnosed multiple myeloma (NDMM), according to new data from the FUMANBA-2 study (NCT05181501).1. Updated data from the study...

Eque-cel Demonstrates High PFS in Newly Diagnosed, High-Risk Multiple Myeloma

Donanemab-azbt is the first and only amyloid plaque-targeting therapy approved for adults with early symptomatic Alzheimer disease. The FDA granted approval for donanemab-azbt for the treatment of adults with early symptomatic Alzheimer disease.1. The novel agent, which will be marketed as Kisunla, was developed by Eli Lilly and Company and...

FDA Approves Donanemab for Early Alzheimer Disease

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back. To be able to intervene faster and on a more targeted basis, researchers at Charité – Universitätsmedizin Berlin, the Berlin Institute of Health at Charité (BIH), and the Max Delbrück Center teamed up with other partners for a comprehensive study of this disease at the molecular level. The team now describes how highly aggressive types of tumors can be detected early on in an article published in the journal Nature Cancer.* They show how changes in genetic material affect the protein profile of the tumor cells, and thus the mechanisms involved in the disease.

Study Sheds Light on Early Development of Multiple Myeloma

CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD. Data from a phase 1 trial (NCT05122546) recently published in Nature Medicine suggest that...

Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer

In the realm of lymphoma and chronic lymphocytic leukemia (CLL), and of the treatments that address them, a global survey of nearly 7000 patients proves there’s a long way to go to eliminate cancer-related fatigue from their lives. Cancer-related fatigue (CRF) unfortunately remains an unmet need: prevalent, underreported, poorly...

Tired of It: Cancer-Related Fatigue in Lymphoma, CLL

Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer. Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymph nodes. These are small structures in the neck, armpits,...

What is the role of PET scans in non-Hodgkin’s lymphoma?

IRONMAN trial highlighted that anemia severity and TSAT < 20% are key indicators for identifying patients with heart failure who may benefit from intravenous iron therapy. The IRONMAN trial aimed to clarify the relationship between iron deficiency, as indicated by various blood tests, and the response to intravenous iron therapy in patients with heart failure, according to research presented in the European Heart Journal. Conducted on 1,137 patients with heart failure and reduced ejection fraction (≤45%), the study investigated the impact of baseline anemia severity, serum ferritin, and transferrin saturation (TSAT) on the response to intravenous ferric derisomaltose (FDI) compared to usual care.

IV Iron Therapy Benefits Patients With Heart Failure, Severe Anemia, and Low TSAT

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

NewSantaAna

The FBI has seen a rise in scams targeting timeshare owners. In this kind of scam, criminals con these part-time property owners into shelling out hefty sums of cash, all under false pretenses related to their timeshare properties.

FBI warns that Mexican cartels are targeting Americans with timeshare scams

Newark, NJ

Morristown Minute

NEWARK, N.J. – Eight individuals associated with the "793 Bloods" street gang, a subset of the national Bloods gang, have been charged for their roles in a Newark-based drug trafficking organization, U.S. Attorney Philip R. Sellinger announced.

Eight '793 Bloods' Gang Members Charged in Newark Drug Network

Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma. Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer, myelodysplastic syndrome (MDS), colorectal cancer (CRC), endometrial cancer, and follicular...

Oncology Drugs Approved by the FDA in June 2024

Ali Carney, 46, of Newark, received a 65-month prison sentence for conspiring to distribute narcotics, including fentanyl and heroin, and possessing with intent to distribute fentanyl, according to U.S. Attorney Philip R. Sellinger.

Gang Member Sentenced to 65 Months for Drug Trafficking

A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention. ABSTRACT. Objectives: Chronic kidney disease (CKD) is a widely prevalent disease with heterogeneous disease progression. Prior study findings suggest...

Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden

SurvivorNet

WWE superstar Roman Reigns, aka Joe Anoai, has lived with chronic myeloid leukemia (CML) since he was 22 years old. He’s currently in remission and takes regular medication as a maintenance therapy.

Wrester Roman Reigns, 39, Makes Triumphant Return To The Ring, The Superstar Leukemia Survivor Offers Hope for Young Cancer Patients

Health

Medically reviewed by Gagandeep Brar, MDMedically reviewed by Gagandeep Brar, MDLung cancer is a type of cancer that grows in your lung tissue. Stages of cancer span from 0-4, with stage 4 being the most advanced stage of lung cancer. Lung cancer is often diagnosed in the later stages because symptoms may be difficult to detect before stage 3 or 4. There are two main types of lung cancer—small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).Small cell lung cancer (SCLC) makes up about 10-15% of all lung cancer cases, and non-small cell lung cancer (NSCLC) makes up...

Stage 4 Lung Cancer

Patients with atrial fibrillation (AF) on low doses of direct oral anticoagulants (DOACs) have more bleeding episodes than those on standard doses, according to a study published online June 6 in Blood Advances. Gualtiero Palareti, M.D., from Fondazione Arianna Anticoagulazione in Bologna, Italy, and colleagues collected venous blood at 15...

Low Dose Direct Oral Anticoagulants in Patients With Atrial Fibrillation Tied to Higher Bleeding Incidence vs Standard Doses

New Jersey State

NEWARK, N.J. – Naiem Moore, 34, of Newark, admitted to possessing cocaine and heroin for distribution and illegally possessing a firearm as a convicted felon, U.S. Attorney Philip R. Sellinger announced. Moore entered his guilty plea before U.S. District Judge Madeline Cox Arleo in Newark federal court.

Man Admits Drug Trafficking & Illegal Firearm Possession

SAN DIEGO — Those with migraine who switched from an oral triptan to ubrogepant reported superior outcomes compared with patients who chose another triptan,, according to data presented at the American Headache Society Annual Scientific Meeting. “Most treatment guidelines in the United States recommend that patients cycle through at...

Patients with migraine report superior outcomes with ubrogepant compared to triptans

NewsBreak

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and...

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

Comments / 0